

Supplementary Materials

Supp. Table 1

Supp. Table 1: *Incidence of hospitalization and AKI 12 months before and after the administration of Vedolizumab*

	12 months <i>before</i> administration of Vedolizumab		12 months <i>after</i> the administration of Vedolizumab	
	Hospitalization	Prerenal AKI	Hospitalization	Prerenal AKI
Case 1	1	1	0	0
Case 2	0	0	0	0
Case 3	1	1	0	0

*acute kidney injury

Supplementary References

S1. Singh U, Singh B, Bellini MI. Immunosuppressive regimens and outcomes of inflammatory bowel disease patients requiring kidney transplantation. *World J Transplant.* 2022 Feb 18;12(2):21-23. doi: 10.5500/wjt.v12.i2.21. PMID: 35211378; PMCID: PMC8855143.

S2. Colombel JF, Sands BE, Rutgeerts P, Sandborn W, Danese S, D'Haens G, Panaccione R, Loftus EV Jr, Sankoh S, Fox I, Parikh A, Milch C, Abhyankar B, Feagan BG. The safety of vedolizumab for ulcerative colitis and Crohn's disease. *Gut.* 2017 May;66(5):839-851. doi: 10.1136/gutjnl-2015-311079. Epub 2016 Feb 18. PMID: 26893500; PMCID: PMC5531223.

S3. Subhaharan D, Ramaswamy PK, Francisco S, Ishaq N. Vedolizumab-Induced Acute Interstitial Nephritis in Ulcerative Colitis. *ACG Case Rep J.* 2022 Jun 24;9(6):e00788. doi: 10.14309/crj.0000000000000788. PMID: 35765681; PMCID: PMC9232362.

S4. Spadaccini M, Aghemo A, Caprioli F, Lleo A, Invernizzi F, Danese S, Donato MF. Safety of vedolizumab in liver transplant recipients: A systematic review. *United European Gastroenterol J.* 2019 Aug;7(7):875-880. doi: 10.1177/2050640619858050. Epub 2019 Jun 20. PMID: 31428411; PMCID: PMC6683639.

S5. Wright AP, Fontana RJ, Stidham RW. Vedolizumab is safe and effective in moderate-to-severe inflammatory bowel disease following liver transplantation. *Liver Transplant.* 2017;23(7):968-971.

S6. Szczepanik, A. et al. The use of non-transplant biologics in solid organ transplant recipients: A practical review for the frontline clinician. *Clinical Transplantation.* 2022;36(7):e14743.